A Phase 2 Multicenter, Open Label, Randomized Study of Two Titration Regimens of Oral CXA-10 in Subjects With Primary Focal Segmental Glomerulosclerosis (FSGS)
Latest Information Update: 06 Nov 2021
At a glance
- Drugs IMR-261 (Primary)
- Indications Focal segmental glomerulosclerosis
- Focus Therapeutic Use
- Acronyms FIRSTx
- Sponsors Complexa
- 31 Jul 2020 Status changed from active, no longer recruiting to completed.
- 04 Jun 2020 Planned End Date changed from 1 Apr 2021 to 1 Dec 2021.
- 04 Jun 2020 Planned primary completion date changed from 1 Apr 2021 to 1 Dec 2021.